(Q34573821)

3 August 2017

1 reference

8 February 2021

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program (English)

1 reference

3 August 2017

1 reference

10 November 2020

1 reference

8 February 2021

1 reference

inferred from abstract

1 reference

1 reference

4

Francesco M Marincola

1 reference

3 August 2017

2

Patrick Hwu

1 reference

3 August 2017

James M Balwit

1

1 reference

3 August 2017

Walter J Urba

series ordinal

3

1 reference

3 August 2017

language of work or name

1 reference

31 January 2011

5 references

Journal of Translational Medicine

3 August 2017

3 April 2019

25 June 2019

10 November 2020

8 February 2021

5 references

3 August 2017

3 April 2019

25 June 2019

10 November 2020

8 February 2021

9

1 reference

3 August 2017

18

1 reference

Creative Commons Attribution 2.0 Generic

3 August 2017

4 references

3 April 2019

25 June 2019

10 November 2020

on focus list of Wikimedia project

8 February 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1479-5876-9-18

0 references

cites work

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038923

Immunotherapy of Malignant Disease

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21281484

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1479-5876-9-18

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference